SCHEMBL2219161

SCHEMBL2219161

Cc1onc(-c2ccccc2)c1CN[C@H](C)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
GABRA5 P31644 6/20 0.55
NPSR1 Q6W5P4 1/20 0.55
PKM P14618 2/20 0.52
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.47
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
MAPT P10636 2/20 0.46
PLA2G1B P04054 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655693 0.89 ALDH1A1 (0.53) ALDH1A1GABRA5NPSR1PKMTDP1
SCHEMBL2218827 0.89 ALDH1A1 (0.53) ALDH1A1GABRA5NPSR1PKMTDP1
SCHEMBL14438335 0.87 ALDH1A1 (0.59) ALDH1A1GABRA5NPSR1PKMTDP1
SCHEMBL2217114 0.81 GABRA5 (0.48) ALDH1A1GABRA5NPSR1PKMTDP1
SCHEMBL5018927 0.76 PTGS1 (0.54) ALDH1A1GABRA5NPSR1PKMPTGS1
SCHEMBL17040356 0.76 ALDH1A1 (0.67) ALDH1A1GABRA5NPSR1PKMKDM4E
SCHEMBL17037447 0.74 ALDH1A1 (0.65) ALDH1A1GABRA5NPSR1PKMKDM4E
SCHEMBL256699 0.74 PTGS1 (0.59) ALDH1A1GABRA5NPSR1PKMPTGS1
SCHEMBL286436 0.72 PTGS1 (0.58) ALDH1A1GABRA5NPSR1PKMTDP1
SCHEMBL107436 0.72 PTGS1 (0.58) ALDH1A1GABRA5NPSR1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334317-B2 Calcium receptor modulating agents AMGEN INC. (US) 2012-12-18 US claimed
EP-2212284-B1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC (US) 2014-04-30 EP disclosed
EP-2212284-B1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC (US) 2014-04-30 EP disclosed
US-8334317-B2 Calcium receptor modulating agents AMGEN INC. (US) 2012-12-18 US disclosed
US-8334317-B2 Calcium receptor modulating agents AMGEN INC. (US) 2012-12-18 US disclosed
US-8334317-B2 Calcium receptor modulating agents AMGEN INC. (US) 2012-12-18 US disclosed
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-07-21 US disclosed
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-07-21 US disclosed
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS CASR, CALCR, RYR1 ALDH1A1 3977/4885GABRA5 388/4885NPSR1 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.